<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30159125</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1949-2553</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <Issue>61</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Oncotarget</Title>                <ISOAbbreviation>Oncotarget</ISOAbbreviation>            </Journal>            <ArticleTitle>Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX.</ArticleTitle>            <Pagination>                <MedlinePgn>31820-31831</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25806</ELocationID>            <Abstract>                <AbstractText>Protein methyltransferase SUV39H2 was reported to methylate histone H2AX at lysine 134 and enhance the formation of phosphorylated H2AX (γ-H2AX), which causes chemoresistance of cancer cells. We found that a series of imidazo[1,2-<i>a</i>]pyridine compounds that we synthesized could inhibit SUV39H2 methyltransferase activity. One of the potent compounds, OTS193320, was further analyzed in <i>in vitro</i> studies. The compound decreased global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggered apoptotic cell death. Combination of OTS193320 with doxorubicin (DOX) resulted in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX. Further optimization of inhibitors and their <i>in vivo</i> analysis identified a compound, OTS186935, which revealed significant inhibition of tumor growth in mouse xenograft models using MDA-MB-231 breast cancer cells and A549 lung cancer cells without any detectable toxicity. Our results suggest that the SUV39H2 inhibitors sensitize cancer cells to DOX by reduction of γ-H2AX levels in cancer cells, and collectively demonstrate that SUV39H2 inhibition warrants further investigation as a novel anti-cancer therapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Vougiouklakis</LastName>                    <ForeName>Theodore</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Saloura</LastName>                    <ForeName>Vassiliki</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Jae-Hyun</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Takamatsu</LastName>                    <ForeName>Naofumi</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>OncoTherapy Science Inc., Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miyamoto</LastName>                    <ForeName>Takashi</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>OncoTherapy Science Inc., Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nakamura</LastName>                    <ForeName>Yusuke</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, The University of Chicago, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matsuo</LastName>                    <ForeName>Yo</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>OncoTherapy Science Inc., Kawasaki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncotarget</MedlineTA>            <NlmUniqueID>101532965</NlmUniqueID>            <ISSNLinking>1949-2553</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Cell Biol. 2003 Jul;5(7):675-9</RefSource>                <PMID Version="1">12792649</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Radiother Oncol. 2011 Oct;101(1):39-45</RefSource>                <PMID Version="1">21840613</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2011 Jul;121(7):2750-67</RefSource>                <PMID Version="1">21633166</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Apr 12;295(14):1658-67</RefSource>                <PMID Version="1">16609087</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gynecol Oncol. 2011 Apr;121(1):206-11</RefSource>                <PMID Version="1">21185067</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2013 Aug 8;122(6):1017-25</RefSource>                <PMID Version="1">23801631</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2008 Mar;8(3):193-204</RefSource>                <PMID Version="1">18256616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Jul 10;6(19):16939-50</RefSource>                <PMID Version="1">26183527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Cell Biol. 2004 Aug;6(8):731-40</RefSource>                <PMID Version="1">15235609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2010 Nov;124(1):133-40</RefSource>                <PMID Version="1">20697801</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2007 Dec 14;28(5):739-45</RefSource>                <PMID Version="1">18082599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Oncol Rep. 2015 Apr;17(4):15</RefSource>                <PMID Version="1">25708799</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2008 Mar 13;358(11):1148-59</RefSource>                <PMID Version="1">18337604</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Dec 6;492(7427):108-12</RefSource>                <PMID Version="1">23051747</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biol. 2001 Apr 30;153(3):613-20</RefSource>                <PMID Version="1">11331310</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Jul 5;7(27):42527-42538</RefSource>                <PMID Version="1">27285764</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Dec 22;6(41):43162-71</RefSource>                <PMID Version="1">26586479</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2011 Jul 12;20(1):53-65</RefSource>                <PMID Version="1">21741596</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Apr 19;7(16):22846-56</RefSource>                <PMID Version="1">26988914</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neoplasia. 2011 Aug;13(8):676-84</RefSource>                <PMID Version="1">21847359</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2014 Apr;105(4):370-88</RefSource>                <PMID Version="1">24484288</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Res. 2015 Feb;13(2):293-304</RefSource>                <PMID Version="1">25280969</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Oncol. 2015 Oct;8(5):368-75</RefSource>                <PMID Version="1">26500027</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2014 May;10(7):1215-37</RefSource>                <PMID Version="1">24947262</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2015 Sep;26 Suppl 5:v8-30</RefSource>                <PMID Version="1">26314782</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 Apr 20;24(12):1940-9</RefSource>                <PMID Version="1">16622270</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2002 May 3;296(5569):922-7</RefSource>                <PMID Version="1">11934988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Jan 19;7:40664</RefSource>                <PMID Version="1">28102297</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Commun. 2014 Dec 09;5:5691</RefSource>                <PMID Version="1">25487737</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2012;5:309-14</RefSource>                <PMID Version="1">23180966</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Manag Res. 2018 Jan 15;10:91-103</RefSource>                <PMID Version="1">29391830</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95</RefSource>                <PMID Version="1">10959836</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2006 Feb;97(2):113-8</RefSource>                <PMID Version="1">16441421</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2010 Oct;123(3):725-31</RefSource>                <PMID Version="1">20020197</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">SUV39H2</Keyword>            <Keyword MajorTopicYN="N">methyltransferase</Keyword>            <Keyword MajorTopicYN="N">small-molecule inhibitor</Keyword>            <Keyword MajorTopicYN="N">γ-H2AX</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST N.T., T.M., and Y.M. are employees of OncoTherapy Science Inc. Y.N. is a stockholder and a scientific adviser of OncoTherapy Science Inc. J.P. is a scientific adviser of OncoTherapy Science Inc. No potential conflicts of interest were disclosed by the other authors.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30159125</ArticleId>            <ArticleId IdType="doi">10.18632/oncotarget.25806</ArticleId>            <ArticleId IdType="pii">25806</ArticleId>            <ArticleId IdType="pmc">PMC6112750</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>